Related Experiment Video
Updated: Jun 1, 2026

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
Published on: August 1, 2019
RGD-modified angiogenesis inhibitor HM-3 dose: dual function during cancer treatment
Hanmei Xu1, Li Pan, Yinling Ren
1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, PR China. xuhanmei@cpu.edu.cn
Abstract:
In the present study, we have undertaken pharmacodynamic studies of HM-3 in vitro and in vivo. A dual function of HM-3 with various doses was observed. HM-3 at low dose revealed obvious anticancer activity. In contrast, HM-3 at high dose had a tendency to promote tumorigenesis and tumor metastasis. Microarray analysis demonstrated that HM-3 at high dose could up-regulate the transcription of AKT1 and MEK1, which resulted in the promotion of tumorigenesis and metastasis. Therefore, the dose of angiogenesis inhibitors plays a critical role in cancer treatment. In order to achieve the ideal effect of angiogenesis inhibitor drugs on cancer treatment, a ful exploration of administration dose, frequency, and period for this kind of drugs is highly desired.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle

